Furthermore, it has been observed that patients with MAFLD-HCC have less severe liver damage and dysfunction than patients with HCV-related HCC, as indicated by higher serum albumin, lower serum bilirubin, and lower rates of ascites. This evidence concerns the gene ALB and hepatocellular carcinoma.